Esperion Therapeutics, Inc. (ESPR)
NASDAQ
Market Cap
$500.49M
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
663 of 963
Rank in Industry
42 of 59
Largest Insider Buys in Sector
ESPR Stock Price History Chart
ESPR Stock Performance
About Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Insider Activity of Esperion Therapeutics, Inc.
Over the last 12 months, insiders at Esperion Therapeutics, Inc. have bought $0 and sold $51,657 worth of Esperion Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Esperion Therapeutics, Inc. have bought $4.34M and sold $98,014 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 23,091 shares for transaction amount of $36,285 was made by CARROLL J MARTIN (director) on 2023‑05‑11.
List of Insider Buy and Sell Transactions, Esperion Therapeutics, Inc.
| 2024-11-19 | Sale | Chief Commercial Officer | 197 <0.0001% | $2.17 | $427 | +11.55% | ||
| 2024-10-17 | Sale | Chief Commercial Officer | 107 <0.0001% | $2.12 | $227 | +17.06% | ||
| 2024-09-17 | Sale | President and CEO | 14,550 0.0075% | $1.80 | $26,132 | +19.10% | ||
| 2024-09-17 | Sale | Chief Commercial Officer | 2,608 0.0013% | $1.78 | $4,650 | +19.10% | ||
| 2024-08-19 | Sale | Chief Commercial Officer | 211 0.0001% | $1.95 | $411 | +7.37% | ||
| 2024-07-17 | Sale | Chief Medical Officer | 917 0.0005% | $2.60 | $2,383 | -22.14% | ||
| 2024-07-17 | Sale | Chief Commercial Officer | 108 <0.0001% | $2.59 | $279 | -22.14% | ||
| 2024-06-18 | Sale | Chief Medical Officer | 3,285 0.0019% | $2.87 | $9,418 | -23.90% | ||
| 2024-06-18 | Sale | Chief Commercial Officer | 2,540 0.0015% | $2.86 | $7,254 | -23.90% | ||
| 2024-05-17 | Sale | Chief Commercial Officer | 192 0.0001% | $2.48 | $477 | -9.36% | ||
| 2023-09-20 | Sale | Chief Commercial Officer | 742 0.0008% | $1.25 | $924 | +80.87% | ||
| 2023-08-18 | Sale | Chief Commercial Officer | 243 0.0003% | $1.41 | $344 | +43.79% | ||
| 2023-07-19 | Sale | Chief Commercial Officer | 106 0.0001% | $1.58 | $168 | +33.12% | ||
| 2023-06-21 | Sale | Chief Commercial Officer | 603 0.0008% | $1.48 | $894 | +33.80% | ||
| 2023-05-17 | Sale | Chief Commercial Officer | 219 0.0003% | $1.62 | $356 | -9.09% | ||
| 2023-05-11 | director | 23,091 0.031% | $1.57 | $36,285 | +6.71% | |||
| 2023-05-10 | director | 8,409 0.011% | $1.49 | $12,545 | +8.90% | |||
| 2023-05-10 | director | 8,111 0.0106% | $1.50 | $12,126 | +8.90% | |||
| 2023-05-09 | President and CEO | 20,000 0.0226% | $1.26 | $25,192 | +11.27% | |||
| 2023-04-19 | Sale | Chief Medical Officer | 938 0.0012% | $1.27 | $1,192 | +15.86% |
Insider Historical Profitability
15.63%
| Koenig Sheldon L. | President and CEO | 752266 0.3818% | $2.54 | 2 | 6 | +3.99% |
| Foody Joanne M. | Chief Medical Officer | 272862 0.1385% | $2.54 | 0 | 8 | |
| Warren Eric | Chief Commercial Officer | 162355 0.0824% | $2.54 | 1 | 21 | <0.0001% |
| BIOTECH TARGET N V | 10 percent owner | 4477964 2.2727% | $2.54 | 21 | 0 | <0.0001% |
| DOMAIN PARTERS VII L P | 10 percent owner | 2566935 1.3028% | $2.54 | 2 | 0 | +89.57% |
| Alta Partners VIII, L.P. | 10 percent owner | 2552189 1.2953% | $2.54 | 2 | 0 | +89.57% |
| TREU JESSE I | 10 percent owner | 2066935 1.049% | $2.54 | 1 | 0 | +8.67% |
| BLAIR JAMES C | 10 percent owner | 2066935 1.049% | $2.54 | 1 | 0 | +8.67% |
| DOVEY BRIAN H | 10 percent owner | 2066935 1.049% | $2.54 | 1 | 0 | +8.67% |
| SCHOEMAKER KATHLEEN K | 10 percent owner | 2066935 1.049% | $2.54 | 1 | 0 | +8.67% |
| Halak Brian K | 10 percent owner | 2066935 1.049% | $2.54 | 1 | 0 | +8.67% |
| Aisling Capital II LP | 10 percent owner | 1837125 0.9324% | $2.54 | 1 | 2 | +8.67% |
| JANNEY DANIEL | director | 1359967 0.6902% | $2.54 | 2 | 1 | +89.57% |
| Boxer Capital, LLC | 10 percent owner | 1101250 0.5589% | $2.54 | 0 | 2 | |
| GOLDSTEIN DOV A MD | director | 837125 0.4249% | $2.54 | 1 | 4 | +8.67% |
| NEWTON ROGER S | director | 548726 0.2785% | $2.54 | 1 | 9 | +8.67% |
| LANGE LOUIS G | director | 197703 0.1003% | $2.54 | 1 | 0 | +8.67% |
| MAYLEBEN TIMOTHY M | President & CEO | 111998 0.0568% | $2.54 | 14 | 0 | <0.0001% |
| Looker Benjamin | General Counsel | 83663 0.0425% | $2.54 | 0 | 2 | |
| CARROLL J MARTIN | director | 36500 0.0185% | $2.54 | 3 | 0 | +9.18% |
| DP VII ASSOCIATES LP | 10 percent owner | 35253 0.0179% | $2.54 | 1 | 0 | +8.67% |
| Longitude Capital Partners, LLC | 10 percent owner | 28186 0.0143% | $2.54 | 1 | 4 | +8.67% |
| ENRIGHT PATRICK G | director | 18361 0.0093% | $2.54 | 1 | 5 | +8.67% |
| Bartram Richard | Chief Financial Officer | 11092 0.0056% | $2.54 | 0 | 1 | |
| ROCAMBOLI STEPHEN | director | 8111 0.0041% | $2.54 | 1 | 0 | +8.9% |
| MCGOVERN MARK E | director | 5000 0.0025% | $2.54 | 2 | 0 | +31.56% |
| Lalwani Narendra D. | Chief Operating Officer | 5000 0.0025% | $2.54 | 1 | 0 | +251.57% |
| OMENN GILBERT S | director | 1000 0.0005% | $2.54 | 3 | 0 | +59.71% |
| VITULLO NICOLE | director | 0 0% | $2.54 | 1 | 3 | +8.67% |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| OrbiMed | $36.74M | 7.24 | 13.71M | New | +$36.74M | 0.28 | |
| Bellevue Group | $26.65M | 5.25 | 9.94M | +136.52% | +$15.38M | 0.41 | |
| Wasatch Advisors | $24.47M | 4.82 | 9.13M | +2.68% | +$639,297.92 | 0.13 | |
| The Vanguard Group | $23.66M | 4.66 | 8.83M | +71.8% | +$9.89M | <0.0001 | |
| Great Point Partners | $21.44M | 4.22 | 8M | New | +$21.44M | 3.59 | |
| Woodline Partners LP | $21.23M | 4.18 | 7.92M | +2,628.21% | +$20.45M | 0.18 | |
| Millennium Management LLC | $15.23M | 3 | 5.68M | +64.71% | +$5.98M | 0.01 | |
| D. E. Shaw & Co. | $13.78M | 2.72 | 5.14M | +323.96% | +$10.53M | 0.01 | |
| Bank of America | $12.18M | 2.4 | 4.55M | +2,474.69% | +$11.71M | <0.01 | |
| Kairos Capital Management Lp | $11.16M | 2.2 | 4.17M | -45.8% | -$9.43M | 5.35 | |
| Two Sigma | $10.65M | 2.1 | 3.98M | +70.3% | +$4.4M | 0.02 | |
| Meditor Group Ltd | $10.16M | 2 | 3.79M | 0% | +$0 | 14.93 | |
| Two Sigma Advisers LP | $9.57M | 1.88 | 3.57M | +66.3% | +$3.81M | 0.02 | |
| Goldman Sachs | $9.02M | 1.78 | 3.36M | +218.16% | +$6.18M | <0.01 | |
| Citadel Advisors LLC | $9.01M | 1.78 | 3.36M | +627.31% | +$7.77M | 0.01 | |
| BlackRock | $7.61M | 1.5 | 2.84M | +34.36% | +$1.95M | <0.0001 | |
| Marshall Wace | $5.94M | 1.17 | 2.22M | +384.09% | +$4.71M | 0.01 | |
| Renaissance Technologies | $5.67M | 1.12 | 2.12M | +49.04% | +$1.87M | 0.01 | |
| JPMorgan Chase | $5.59M | 1.1 | 2.09M | +11.95% | +$596,651.01 | <0.0001 | |
| Susquehanna International Group | $5.48M | 1.08 | 2.05M | +47.15% | +$1.76M | 0.01 | |
| Geode Capital Management | $4.7M | 0.93 | 1.75M | +57.63% | +$1.72M | <0.0001 | |
| Morgan Stanley | $4.4M | 0.87 | 1.64M | +48.63% | +$1.44M | <0.0001 | |
| Qube Research & Technologies | $4.31M | 0.85 | 1.61M | +269.29% | +$3.14M | 0.01 | |
| PLATINUM INVESTMENT MANAGEMENT LTD | $4.28M | 0.84 | 1.6M | -43.16% | -$3.25M | 0.06 | |
| Parkman Healthcare Partners Llc | $3.06M | 0.6 | 1.14M | -19.81% | -$756,582.77 | 0.38 | |
| Jane Street Capital | $2.64M | 0.52 | 983,343 | +256.74% | +$1.9M | <0.01 | |
| Schonfeld Group | $2.54M | 0.5 | 947,506 | -13.18% | -$385,442.80 | 0.02 | |
| Jacobs Levy Equity Management | $1.89M | 0.37 | 704,097 | -33.44% | -$948,149.18 | 0.01 | |
| State Street | $1.48M | 0.29 | 551,249 | +43.65% | +$448,899.90 | <0.0001 | |
| Gsa Capital Partners Llp | $1.2M | 0.24 | 449,129 | -60.19% | -$1.82M | 0.1 | |
| Man Group Plc | $1.18M | 0.23 | 440,770 | +103.13% | +$599,744.00 | <0.01 | |
| Hrt Financial Llc | $1.18M | 0.23 | 442,030 | +821.45% | +$1.06M | 0.01 | |
| Wellington Management Company | $967,016.00 | 0.19 | 360,827 | New | +$967,016.00 | <0.0001 | |
| Citigroup | $956,085.00 | 0.19 | 356,748 | -5.62% | -$56,931.26 | <0.01 | |
| Northern Trust | $827,254.00 | 0.16 | 308,677 | +30.47% | +$193,185.04 | <0.0001 | |
| Squarepoint Ops LLC | $804,804.00 | 0.16 | 300,300 | +242.37% | +$569,735.84 | <0.01 | |
| Pinnacle Associates, Ltd. | $764,347.00 | 0.15 | 285,204 | +0.69% | +$5,223.32 | 0.01 | |
| Cubist Systematic Strategies | $732,423.00 | 0.14 | 273,292 | +47.75% | +$236,700.42 | 0.01 | |
| Parallel Advisors, LLC | $640,520.00 | 0.13 | 239,000 | -50% | -$640,520.00 | 0.02 | |
| Walleye Capital | $610,048.00 | 0.12 | 227,630 | +6.37% | +$36,528.38 | <0.01 | |
| Davidson Kempner Capital Management | $594,027.00 | 0.12 | 222,482 | 0% | +$0 | 0.02 | |
| Nj State Employees Deferred Compensation Plan | $522,935.00 | 0.1 | 195,125 | 0% | +$0 | 0.05 | |
| Hightower Advisors | $496,000.00 | 0.1 | 187,166 | +277.59% | +$364,639.47 | <0.01 | |
| Marathon Trading Investment Management Llc | $456,940.00 | 0.09 | 170,500 | +711.9% | +$400,660.00 | 0.1 | |
| Susquehanna Fundamental Investments Llc | $446,105.00 | 0.09 | 166,457 | New | +$446,105.00 | 0.02 | |
| Balyasny Asset Management Llc | $426,222.00 | 0.08 | 159,038 | +327.66% | +$326,558.12 | <0.01 | |
| Ubs Oconnor Llc | $381,680.00 | 0.08 | 142,418 | -72.98% | -$1.03M | 0.02 | |
| Group One Trading | $323,634.00 | 0.06 | 120,759 | New | +$323,634.00 | <0.01 | |
| Point72 Asia Singapore Pte Ltd | $306,514.00 | 0.06 | 114,371 | +466.19% | +$252,378.05 | 0.03 | |
| Fidelity Investments | $281,859.00 | 0.06 | 105,171 | -62.01% | -$460,090.17 | <0.0001 |
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.